Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.
MULTICELL TECHNOLOGIES INCORPORATED (OTCBB: MCET)
"Up 176.47% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/MCET.php
MultiCell Technologies, Inc., a biopharmaceutical company, develops and commercializes therapeutics based on a portfolio of patented drug development technology platforms. It involves in the research and development of degenerative neurological diseases, including multiple sclerosis (MS) and cancer. The company’s therapeutic pipeline includes MCT-125, a Phase IIb therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-175, a preclinical therapeutic candidate for the treatment of relapsing-remitting MS; MCT-465, a preclinical adjuvant therapeutic candidate for the treatment of TLR3+ cancers; and MCT-475, a preclinical therapeutic candidate for the treatment of TLR3+ breast cancer. In addition, it has patented the ‘Sybiol’ synthetic bio-liver device to produce therapeutic proteins using BioFactories technology. The company was formerly known as Exten Ventures, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is based in Woonsocket, Rhode Island.
MCET News:
August 19 - MultiCell Technologies is Granted U.S. Patent for Immortalized Human Liver Cell Lines
MultiCell Strengthens Its Liver Cancer Drug Target Identification and Cancer Stem Cell Research Program
MultiCell Technologies, Inc. (OTCBB: MCET) announced that it has been granted U.S. patent 7,566,567 by the United States of America Patent and Trademark Office covering its Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines.
The Fa2N-4 and Ea1C-35 immortalized human hepatocyte cell lines were derived from normal human liver cells, and are nontumorigenic, stable in culture, and produce therapeutic plasma proteins in cell culture. The Fa2N-4 cell line has also been engineered to function as a proxy for normal human liver cells for use in performing drug toxicity assays. MultiCell has licensed several pharmaceutical companies rights to use the Fa2N-4 cell line for drug toxicity applications including Pfizer, Bristol-Myers Squibb, and Eisai Pharmaceuticals. MultiCell licensed Corning, Inc. to sell the Fa2N-4 cell line and media within the drug discovery and life science research markets for drug toxicity (Tox) applications as well as for drug adsorption, distribution, metabolism and excretion (ADME) studies. MultiCell retained worldwide exclusive ownership of the Fa2N-4 and Ea1C-35 cell lines for all applications other than ADME/Tox, including drug target identification and using the cell lines for the production of therapeutic plasma proteins.
MultiCell also owns exclusive worldwide rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of human liver stem cells. MultiCell previously announced it had entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of human liver stem cells and human liver cancer.
The role of liver stem cells in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma in humans arises by maturation arrest of liver stem cells. "MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies. "We believe our engineered human liver cell lines will play an important role as proxies for normal human liver cells in our effort to identify drug targets."
The National Cancer Institute (NCI) in 2008 stated there were approximately 21,400 new cases of hepatocellular carcinoma and intrahepatic bile duct cancer in the United States, and approximately 18,400 of those cases resulted in death. Hepatocellular carcinoma, resulting from Hepatitis B and Hepatitis C infection, is the most common cancer in some parts of the world, with more than 1 million new cases diagnosed each year. The NCI also reports that hepatocellular carcinoma is associated with cirrhosis of the liver in 50% to 80% of patients.
AMERIRESOURCE TECHNOLOGIES INCORPORATED (OTC: ARIO)
"Up 100.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/ARIO.php
AmeriResource is a diversified holding company with headquarters in Las Vegas, Nevada. For more information on the Company's subsidiary, visit www.attosolutions.com.
ARIO News:
August 20 - AmeriResource Subsidiary, ATTO Enterprises, Inc., Appoints Interim President
AmeriResource Technologies, Inc. (OTC: ARIO), a diversified holding company, subsidiary, ATTO Enterprises, Inc., appoints Rob Sutton as the interim President of the Company.
Delmar Janovec, CEO of AmeriResource comments, "Rob Sutton brings an extensive knowledge of the ATTO proprietary software that has been developed for the shipping-freight industry. His expertise and background provides a valuable component to the current business model of ATTO which is a key to retaining its current clients as well as the addition of new clients. We look forward to working with Rob to achieve the business objectives of ATTO Enterprises while tapping into the enormous shipping-freight markets."
Mr. Sutton, President of ATTO Enterprises, Inc., remarks, "I'm looking forward to working with Mr. Janovec in the further development of ATTO's software platform designed for the shipping-freight industries and expanding its current business model. We are optimistic that with the right management team and financing we can bring on many new clients which spend a significant amount on shipping annually by offering the client various options for its shipping and potentially considerable savings on their shipping expenditures."
The Company is in the process of updating its own website as well as ATTO Solutions website and subsidiary websites that have dated information. We are committed to delivering up to date and accurate information to potential customers and investors alike. Management is working diligently to bring AmeriResource filings current with the SEC and revamping our website to be in compliance with the current information requirements.
ATTO Enterprises Addresses the $600 Billion Shipping-Freight Industry
ATTO Enterprises addresses the shipping expenditures for its clients by providing our software technology that reviews the customer's overall freight systems and expenses to determine if the customer's costs are in line within the industry. Following the analysis, the Company will provide the customer with our findings and potential cost saving projections. If ATTO does not save the customer on its shipping charges, then the customer does not pay. If ATTO saves the customer on its shipping charges, then ATTO shares in the cost savings as our fee for the services. If ATTO Enterprises is able to capture only a fraction of this industry revenue, ATTO will have a bright future.
ANIKA THERAPEUTICS INCORPORATED (NASDAQ: ANIK)
"Up 41.25% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/ANIK.php
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika’s products include ORTHOVISC®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC®, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; a family of aesthetic dermatology products for facial wrinkles and scar remediation marketed in the U.S. by Coapt Systems, Inc.; AMVISC®, AMVISC® Plus, STAARVISC™-II and Shellgel™ injectable viscoelastic HA products for ophthalmic surgery; INCERT®, an HA-based anti-adhesive for surgical applications; ORTHOVISC® mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC™ a single-injection osteoarthritis product based on Anika’s proprietary cross-linking technology and available in Europe, Turkey, and Canada; and next generation products for joint health and aesthetic dermatology based on the Company’s proprietary, chemically modified HA.
ANIK News:
August 18 - Anika Therapeutics Receives Health Canada Approval for MONOVISC
Represents the first approval in North America for its Single-Injection Osteoarthritis Treatment
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
“We are very pleased to be the exclusive distributor of MONOVISC in the Canadian market and will begin aggressively marketing it immediately,” said Bill Chick, VP Product Distribution for Helix BioPharma Corp. “We believe that both patients and physicians stand to benefit from MONOVISC’s unique features: patients will welcome fewer office visits and lower treatment costs, while physicians will appreciate the simplicity of the single-injection regimen.”
“Health Canada approval marks an important next step as we continue to expand the geographic reach of our novel osteoarthritis treatment therapy and establish MONOVISC as the premier single-injection product on the market worldwide,” said Charles H. Sherwood, Ph.D., Anika’s President and Chief Executive Officer. “We are successfully moving forward on our goal of achieving FDA approval for MONOVISC in the U.S. The initial PMA modules have been submitted to the FDA and are currently under review. We expect to submit the final module containing the clinical study data prior to year-end 2009. We are confident that MONOVISC will be as well received in North America as it has been in Europe.”
The Company previously announced that it has completed the clinical segment of the U.S. pivotal trial for MONOVISC, and is now focused on completing the retreatment study for MONOVISC, which is designed to demonstrate the safety and benefit of repeat injections.
ABOUT MONOVISC™
MONOVISC™ is Anika’s next-generation HA-based therapy for treating osteoarthritis that features enhanced durability in a safe, easy-to-use, single injection regimen. MONOVISC is made from highly purified, non-animal, natural hyaluronan. Hyaluronan occurs naturally throughout the body, especially in articular cartilage, synovial fluid in joints and in the skin.
HELICOS BIOSCIENCES CORPORATION (NASDAQ: HLCS)
"Up 25.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/HLCS.php
Helicos BioSciences is a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Helicos' proprietary True Single Molecule Sequencing (tSMS)(TM) technology allows direct measurement of billions of strands of DNA, enabling scientists to perform experiments and ask questions never before possible. Helicos is a recipient of the $1,000 genome grant and is committed to providing scientists the tools to unlock the era of genomic medicine. The company's corporate headquarters are located at One Kendall Square, Building 700, Cambridge, MA 02139, and its telephone number is (617) 264-1800.
HLCS News:
August 20 - Ontario Institute for Cancer Research Takes Delivery of a Helicos Genetic Analysis System
Leaders in the field of cancer genomics to leverage benefits of single molecule sequencing technology
Helicos BioSciences Corporation (Nasdaq: HLCS), a life science company focused on innovative genetic analysis technologies, announced the placement of a Helicos™ Genetic Analysis System at the Ontario Institute for Cancer Research (OICR) with Drs. Tom Hudson and John McPherson.
“We are very excited to be working with such a distinguished institution on the application of our technology to the study of cancer genomics” stated Ron Lowy, Helicos Chief Executive Officer.
The Helicos Genetic Analysis System is the world’s first and only commercially available, single molecule sequencing technology, and enables scientists to conduct revolutionary studies in the fields of genome biology, cancer research, common diseases, and microbiology without DNA ligation or amplification. Genetic analysis with Helicos’s technology eliminates the biases, complexity and errors introduced by DNA amplification, requires minute amounts of starting material, and provides the most direct and accurate view of biological samples.
“The translational cancer research we are conducting at our center can benefit greatly from the advantages of single molecule sequencing” stated Tom Hudson, President and Scientific Director of the OICR. “We hope to use this technology for the unbiased and comprehensive characterization of tumor samples to ultimately lead to discoveries that have a clinical impact.”
ABOUT THE ONTARIO INSTITUTE FOR CANCER RESEARCH
The Ontario Institute for Cancer Research is a new research institute, moving Ontario to the forefront of discovery and innovation. It is dedicated to research in prevention, early detection, diagnosis and treatment of cancer. OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation.
GOLDEN DRAGON HOLDINGS INCORPORATED (OTC: GDHI)
"Up 30.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/GDHI.php
Golden Dragon Holdings, Inc. (GDHI) is a USA publicly traded company that owns and operates Golden Dragon Food & Beverage Import & Export Company of Hong Kong, Ltd. (GDHK) in central Hong Kong. Golden Dragon Holdings, Inc. has agreements with USA food manufacturers. GDHI acts as a buying agent for GDHK, negotiating vendor contracts and services with USA food and beverage industry partners. The company purchases goods and services directly from Golden Dragon Holdings, Inc. The Hong Kong Company plays a strategic role in the importation of products into the Chinese market by leveraging the Closer Economic Partnership Arrangement (CEPA) with China. We distribute some of the most popular USA food and beverage brand products directly into the hypermarkets, supermarkets and convenience stores in China. We are responsible for order fulfillment for our clients in China, as well as providing advertising and promotion (A&P) services for our USA food and beverage products.
GDHI News:
August 20 - Golden Dragon Holdings, Inc. Signs Distribution Agreement With Haorizi Trade Corporation
Golden Dragon Holdings, Inc. (OTC: GDHI) announces that it has signed a distribution and logistics agreement with the Haorizi Trade Corporation www.haorizi.com, a subsidiary of Good Life China. Under this agreement, GDHI will commence the sales and marketing of its products in over 500 convenience stores operated by Haorizi in Beijing.
"We are excited about the partnership with Haorizi; they have tremendous strength and experience in the food and beverage distribution and logistics industry in China. With this partnership we can focus on promoting our products and driving sales which is our true core competency," stated Mr. Frank Yglesias CEO.
ABOUT HAORIZI
Haorizi Trade Corporation (HTC) was established in 1998. Its major business is to provide IT and logistics service for short-term consuming products providers and retailers. Haorizi is one of most successful and fastest growing chain of Convenience Stores in rural areas of Hebei Province, China.
The Company has enjoyed meteoric growth rates over the last 10 years, growing from a mere 8 stores in 1999 to almost 1,600 in 2007, becoming the largest chain store network of convenience stores serving more than 2.4 million people in the rural areas of China.
The Company expects to continue rapid expansion of its retail footprint through the next several years, and plans to begin launching stores in large urban areas beginning in 2008. Current plans call for the Company to expand to 2,200 franchised stores in 2008, and reach upwards of up to 15,000 locations by the end of 2010.
Net Profit is currently projected to exceed the fiscal plan of $2.29 million USD for the 2007 fiscal year by a significant margin, and increase to over $25 million USD by 2011.
BEBIDA BEVERAGE COMPANY (OTC: BBDA)
"Up 14.29% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/BBDA.php
The company, formerly known as Fortis Enterprises, was founded in 2000 and is based in Casselberry, Florida. On Sept. 4, 2008, Renovo Holdings announced that the company had changed its name to Bebida Beverage Company and would be locating the base of the company's North American presence in Las Vegas, NV. Bebida Beverage Company hopes to concentrate operations on the bottled water and enhanced beverage markets of North and South America. Bebida's management will focus the company's business efforts within the United States and key target markets within Latin America.
BBDA News:
August 11 - Bebida Beverages Says CHILLAX With a KOMA UNWIND in 2009
Bebida Beverages Company (OTC: BBDA) and its Koma Unwind brand have announced final can design and flavors have been choose and a September full production is now scheduled for Koma Unwind a brand new "Chillaxation Drink Upon the purchase of Bebida Beverages.
CEO Brian Weber had made early on changes to the product portfolio and the direction of the company for the future growth, prosperity and increased shareholder value.
"We got a little ahead of ourselves when we made this change from an energy drink to a relaxation drink early on,” Weber said. “With the economy picking up, designers and flavor houses at capacity, it took a bit longer for us to get the final product where we wanted.”
“We are very happy with the final product and now taking orders from our many distributors looking to add Koma Unwind to their portfolio in the coming months,” Weber added.
Another change aside from design and flavor recently has been the down size from 20 oz bottle to a 12 oz can. “After extensive research it was really a no brainer, as most people unwinding don't care to drink so much liquid before sleep or 'Chillaxing,'” said VP Daisy Ramirez.
Bebida is also excited about continued interest in its products: Potencia Energy Drink, Potencia Blast Energy Shot, Koma Unwind & Piranha Water. The company has been in talks with several national C-Store retailers about co-branding with its NASCAR Camping World Truck Series team and driver. The opportunities for massive media exposure during the NASCAR events along with the marketing rollout make these deals unbelievably viable for retailers. Their investment in Bebida’s team is more about shelf space and purchase orders than hard cash, which during these economic recovery times is more viable.
“It's pretty simple, they purchase our products (which they do anyway) we give them national media exposure and a rallying point with our race team,” said Weber. “We are always looking for retailers that are interested in participating in these type deals.”
Potencia Energy Drink is a 3-year-old all natural fruit energy drink developed for Latino's but loved by everyone! With the initial flavor of Tamarind and the second flavor mandarin due out soon.
Bebida Beverages Co. is the maker and developer of several beverages, including Piranha Water, Guppy Water, Koma Unwind (Chillaxation Beverage) and Koma Shot.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org/.
Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.
